Hospital, Celgene Fight Over Royalties for Cancer Drugs

A dispute playing out in federal court over a blockbuster cancer treatment underscores the tensions that can surface in an area of growing importance to pharmaceutical and biotechnology companies—their research collaborations and licensing agreements with academia.



from WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304591604579290323037315400.html?mod=pls_whats_news_us_business_f

via IFTTT